COMP <GO>
GKOS vs ABBV // FORWARD P/E MULTIPLE
Glaukos Corporation (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: GKOS 5
— ABBV 9
▲ FORWARD P/E MULTIPLE LEADER: GKOS
LAST: $237.60 (-2.01%) • MKT CAP: $14.35B
forward-pe
34.0x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GKOS VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GKOS | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.70% | 70.20% | -14.50 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -13.70% | 29.00% | -42.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.16% | 3.47% | -3.63 | ABBV | /fcf-yield <GO> |
| Operating Margin | -39.30% | 24.60% | -63.90 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -37.00% | 6.90% | -43.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 32.30% | 8.60% | +23.70 | GKOS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.33 | +20.67 | GKOS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 7.40% | -0.40 | GKOS | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 82.6 | 72.8 | +9.80 | GKOS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 1.15 | -0.11 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 34.0x | 113.1x | -79.10 | GKOS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.35B | $513.86B | -$499.51B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GKOS REV | ABBV REV | GKOS GROSS % | ABBV GROSS % | GKOS FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $507.4M | $61.16B | 55.7% | 70.2% | -$22.5M | $17.82B |
| FY 2024 | $383.5M | $56.33B | 75.5% | 70.0% | -$67.6M | $17.83B |
| FY 2023 | $314.7M | $54.32B | 44.0% | 44.0% | -$71.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GKOS // BETA 1.04
ABBV // BETA 1.15